Pieris Pharmaceuticals: Funding, Investors & Team (Sep 2026)
Using its patented Anticalin® technology, clinical-stage biotechnology business Pieris Pharmaceuticals, Inc. develops unique medications that potentially benefit people with cancer, severe asthma, anaemia, and other medical illnesses with a high unmet medical need. Human proteins called lipocalins that naturally bind, store, and transport a diverse range of chemicals are recombinantly created as anticalins. Almost every target of interest can be virtually bound by our libraries of more than 100 billion unique anticalins.
Pieris Pharmaceuticals has raised $5.0M across 1 funding round on record, the most recent an undisclosed round of $5.0M announced in Jan 2023.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Pieris Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Jan 2023.
Pieris Pharmaceuticals Funding Rounds
Pieris Pharmaceuticals Founders and Leadership Team
No contact details are on record for this team yet.
Pieris Pharmaceuticals Funding Compared to Other Biotechnology Startups
Pieris Pharmaceuticals' latest round of $5.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Pieris Pharmaceuticals in Biotechnology and Boston
Companies Similar to Pieris Pharmaceuticals
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Pieris Pharmaceuticals Funding FAQs
What does Pieris Pharmaceuticals do?
Using its patented Anticalin® technology, clinical-stage biotechnology business Pieris Pharmaceuticals, Inc. develops unique medications that potentially benefit people with cancer, severe asthma, anaemia, and other medical illnesses with a high unmet medical need. Human proteins called lipocalins that naturally bind, store, and transport a diverse range of chemicals are recombinantly created as anticalins. Almost every target of interest can be virtually bound by our libraries of more than 100 billion unique anticalins.
How much funding has Pieris Pharmaceuticals raised?
Pieris Pharmaceuticals has raised $5.0M across 1 round on record. The most recent is an undisclosed round of $5.0M announced in Jan 2023.
When did Pieris Pharmaceuticals last raise funding?
Pieris Pharmaceuticals' most recent funding round on record is an undisclosed round of $5.0M, announced in Jan 2023.
Who founded Pieris Pharmaceuticals?
FundedIQ lists Arne Skerra (Founder) at Pieris Pharmaceuticals.
Where is Pieris Pharmaceuticals headquartered?
Pieris Pharmaceuticals is based in Boston, Massachusetts, United States.
How many employees does Pieris Pharmaceuticals have?
Pieris Pharmaceuticals is in the 101-250 employee band.
How does Pieris Pharmaceuticals' funding compare to other Biotechnology startups?
Pieris Pharmaceuticals' latest round of $5.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Pieris Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Pieris Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.